WO2004103356A3 - Treatment of emotional dysregulation - Google Patents

Treatment of emotional dysregulation Download PDF

Info

Publication number
WO2004103356A3
WO2004103356A3 PCT/US2004/013005 US2004013005W WO2004103356A3 WO 2004103356 A3 WO2004103356 A3 WO 2004103356A3 US 2004013005 W US2004013005 W US 2004013005W WO 2004103356 A3 WO2004103356 A3 WO 2004103356A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
emotional dysregulation
dysregulation
emotional
administering
Prior art date
Application number
PCT/US2004/013005
Other languages
French (fr)
Other versions
WO2004103356A2 (en
Inventor
Albert John Allen
Kathleen Ann Cloutier
David Michelson
Frederick William Reimherr
Original Assignee
Lilly Co Eli
Albert John Allen
Kathleen Ann Cloutier
David Michelson
Frederick William Reimherr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Albert John Allen, Kathleen Ann Cloutier, David Michelson, Frederick William Reimherr filed Critical Lilly Co Eli
Publication of WO2004103356A2 publication Critical patent/WO2004103356A2/en
Publication of WO2004103356A3 publication Critical patent/WO2004103356A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Provided is a method of treating emotional dysregulation comprising administering to a patient in need of such treatment a selective norepinephrine reuptake inhibitor.
PCT/US2004/013005 2003-05-15 2004-05-11 Treatment of emotional dysregulation WO2004103356A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47075203P 2003-05-15 2003-05-15
US60/470,752 2003-05-15

Publications (2)

Publication Number Publication Date
WO2004103356A2 WO2004103356A2 (en) 2004-12-02
WO2004103356A3 true WO2004103356A3 (en) 2005-03-31

Family

ID=33476747

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013005 WO2004103356A2 (en) 2003-05-15 2004-05-11 Treatment of emotional dysregulation

Country Status (1)

Country Link
WO (1) WO2004103356A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113358773B (en) * 2021-05-21 2022-09-13 健民药业集团股份有限公司 Reversed phase liquid chromatography method for detecting atomoxetine hydrochloride enantiomer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021430A1 (en) * 1995-01-11 1996-07-18 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
EP0756869A2 (en) * 1995-07-24 1997-02-05 Eli Lilly And Company Use of duloxetine or of N-alkyl-3-phenyl-(2-alkylthiophenoxy)-propylamines for treating attention-deficit/hyperactivity disorder
WO2002040006A2 (en) * 2000-11-15 2002-05-23 Eli Lilly And Company Treatment of anxiety disorders

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996021430A1 (en) * 1995-01-11 1996-07-18 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
EP0756869A2 (en) * 1995-07-24 1997-02-05 Eli Lilly And Company Use of duloxetine or of N-alkyl-3-phenyl-(2-alkylthiophenoxy)-propylamines for treating attention-deficit/hyperactivity disorder
WO2002040006A2 (en) * 2000-11-15 2002-05-23 Eli Lilly And Company Treatment of anxiety disorders

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EBERHARD G ET AL: "A double-blind randomized study of clomipramine versus maprotiline in patients with idiopathic pain syndromes.", NEUROPSYCHOBIOLOGY. 1988, vol. 19, no. 1, 1988, pages 25 - 34, XP008035312, ISSN: 0302-282X *
MICHELSON DAVID ET AL: "Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies.", BIOLOGICAL PSYCHIATRY, vol. 53, no. 2, 15 January 2003 (2003-01-15), pages 112 - 120, XP008035456, ISSN: 0006-3223 *
SELVINI A ET AL: "Antidepressant treatment with maprotiline in the management of emotional disturbances in patients with acute myocardial infarction: a controlled study.", THE JOURNAL OF INTERNATIONAL MEDICAL RESEARCH. 1976, vol. 4, no. 1, 1976, pages 42 - 49, XP008035313, ISSN: 0300-0605 *
SIMPSON DENE ET AL: "Atomoxetine: A review of its use in adults with attention deficit hyperactivity disorder.", DRUGS, vol. 64, no. 2, 2004, pages 205 - 222, XP008035472, ISSN: 0012-6667 *
SPENCER THOMAS ET AL: "Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.", THE JOURNAL OF CLINICAL PSYCHIATRY. DEC 2002, vol. 63, no. 12, December 2002 (2002-12-01), pages 1140 - 1147, XP008035469, ISSN: 0160-6689 *

Also Published As

Publication number Publication date
WO2004103356A2 (en) 2004-12-02

Similar Documents

Publication Publication Date Title
WO2005046618A3 (en) Methods of treating eczema
WO2005094836A3 (en) Use of loteprednol etabonate for the treatment of dry eye
BRPI0408476A (en) methods to improve skin quality
WO2006078463A3 (en) Method for treating cardiovascular disease
EP1576963A3 (en) Use of botulinum toxin in the treatment of pain due to an infection
NO20074999L (en) Method and preparation for the treatment of peripheral vascular diseases
WO2001060347A3 (en) Method for treating ocular pain
WO2003082260A3 (en) Tuberculosis treatment using pleuromutilin derivatives
MY138732A (en) Conjugated complement cascade inhibitors
WO2007095615A3 (en) Use of benzo-heteroaryl sulfamide derivatives for the treatmentof pain
WO2003024386A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
MXPA03000188A (en) Methods of treating neutrophil-related diseases with topical anesthetics.
DE122009000036I1 (en) Use of dapoxetine, A selective serotonin uptake inhibitor, for the treatment of sexual dysfunction
WO2006039414A3 (en) Treatment method
MXPA03004288A (en) Treatment of anti-depression drug-induced sexual dysfunction with apomorphine.
MY136367A (en) Treatment of cognitive failure
EA200501549A1 (en) APPLICATION OF THE EXPRESSING VECTOR ENCODING IL-18 INHIBITOR FOR THE TREATMENT AND / OR PREVENTION OF THE HEART DISEASE AND THE METHOD OF TREATING THE HEART DISEASE
WO2001066101A3 (en) Treatment of psoriasis
NO20063320L (en) Use of gaboxadol for the treatment of insomnia
AU2002220257A1 (en) Methods of treatment involving human mda-7
EP1585536A4 (en) Method of treatment of conditions by administration of streptolysin o
WO2004103356A3 (en) Treatment of emotional dysregulation
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
WO2005020975A3 (en) Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
WO2005020976A3 (en) Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase